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Therapy of indolent lymphomas with involvement of the central nervous system (CNS) has not been standardized
so far. A 42-year old male patient presented with neurological signs because of leukemic splenic marginal zone
lymphoma (SMZL) manifested in bone marrow, lymph nodes and CNS. Due to the aggressiveness of the disease
and the young age of the patient, an intensive immunochemotherapy followed by high-dose therapy with
busulfan, thiotepa and fludarabine and subsequent unrelated allogeneic stem cell transplantation (alloSCT) was
performed. The haemopoietic stem cells engrafted in time and the patient is doing well (ECOG 0) without evidence
for active lymphoma three years after transplantation. Highly sensitive tests by specific quantitative real-time
polymerase chain reaction for presence of lymphoma cells in blood and bone marrow indicated also a molecular
remission. The reported case shows the feasibility of high-dose therapy and allogeneic stem cell transplantation in
high-risk patients with CNS-involvement of indolent non-Hodgkin’s lymphoma. In addition, the case supports the
hypothesis that the graft-versus lymphoma effect after alloSCT is also active within the CNS.
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Splenic marginal zone lymphoma (sMZL) has usually a
very indolent course and affects the elderly people. Ther-
apy consists of splenectomy and mild chemotherapy
upon clinical course [1–5]. Secondary affection of the
central nervous system by non-Hodgkin’s lymphoma is
associated with a poor prognosis [6]. Here we present
the uncommon case of a young man suffering from a
very aggressive sMZL with primary affection of the CNS
and the treatment with allogeneic stem cell transplant-
ation for consolidation.* Correspondence: william.krueger@uni-greifswald.de
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A 42-year old male presented with paraplegia, reduced vi-
bration sense and neuropathic pain in the legs aggravating
over the last six months. The further medical history was
empty. Clinical examination and computed tomography
revealed generalized lymphadenopathy and splenomegaly.
B-symptoms were absent. Magnetic resonance imaging
(MRI) of the CNS detected a signal intense 9 mm sized le-
sion within the temporal lobe and thickened filaments of
the cauda equina with contrast medium enhancement,
suggestive for a malignant meningeosis (Figure 1). The
LDH has been elevated in serum (284 U/l, upper normal
value: 253 U/l). Electrophoresis and immunofixation gave
no hint for a monoclonal gammopathy.
Peripheral blood showed a lymphocytosis of 34,000/μl
with predominance (92.2% in differential count) of small,
mature and partially villous lymphocytes (Figure 2). The
immunophenotype was compatible with SMZL (CD19+,
CD20+, cy79a+, expression of sIgM, FMC7 and lambda
light chain and partial expression of CD5 and CD38, butral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 MR images of LWS (a-d) and cranium (e-f) at initial diagnosis (a, c, e) and at 24 months after allogeneic transplantation (b, d,
f). The size and the intensity of contrast-agent enhanced structures within CNS have regressed after stem cell transplantation.
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of splenic marginal zone lymphoma was confirmed by
histological examination of a lymph node. In the cere-
brospinal fluid (CSF) lymphoma cells were detected by
morphology (Figure 2) and flow cytometry (Figure 3).
Cytogenetics showed an additional isochromosome 3q
and a translocation t(2;7)(p11;q21-22) in line with the
diagnosis of splenic marginal zone lymphoma. The IgH
rearrangement of lymphoma cells was sequenced to es-
tablish a specific quantitative real time polymerase chain
reaction (PCR) for detection of minimal residual disease
(MRD) (Figure 4). PCR-analysis confirmed malignant
lymphomatosis in CSF.
Therapy was initiated combining immunochemother-
apy including rituximab, high dose methotrexate (MTX)
and cytarabine (Ara-C) plus intrathecal application of
MTX, Ara-C and dexamethasone according the B-ALL
protocol [7]. With exception of persistent slight enlarge-
ment of the spleen, the lymphoma showed a complete
response, including the neurological symptoms.Figure 2 Villous lymphocytes in the peripheral blood (a) and in the cAllogeneic stem cell transplantation (alloSCT) was
scheduled for consolidation since the lymphoma showed
an aggressive behavior in a young patient. The experi-
mental nature of this approach and conventional alter-
natives were discussed comprehensively with the patient
and his wife. It is the only therapy offering the change
of curing. Additionally, the aggressive course and the
uncommon manifestation are suggestive for an early
transformation of lymphoma. After conditioning with
i.v.-Busulfan 6.4 mg/kg bodyweight, Thiotepa 10 mg/kg,
Fludarabin 150 mg/m2 and ATG 6 mg/kg the patient
was allografted with 10.2 x 106 CD34+ cells per kg body-
weight from a matched unrelated donor. Cyclosporine-A
and short-course MTX were given for GvHD-prophy-
laxis. Supportive therapy followed standard conditions
and grade I renal toxicity was noted per the Bearman
criteria [8]. Granulocyte engraftment (1,000 cells/μl) oc-
curred at day +17 and platelets exceeded 20,000/μl at
day +26, independently from transfusion. The patient
developed a cvl-related septicaemia with Enterococcuserebrospinal fluid (b).
Figure 3 a: Kappa (negative) and b: Lambda light (positive, right upper quadrant) chain expression by MZL-cells from cerebrospinal
fluid, FACS-analysis prior to therapy.
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rods. Both complications resolved under adequate anti-
biosis. Donor chimerism in the bone marrow was 100%
at day +43 and the patients was discharged.
Signs of an acute or chronic graft-versus-host disease
were not seen. Control MRIs from the central nervous
systems showed continuing complete regression of the
lymphoma (Figure 1f) Three years after allogeneic stem
cell transplantation the patient is doing well (ECOG 0)
without any neurological abnormalities. Molecular follow-
up of minimal residual disease in blood or marrow by
rtPCR revealed negative results after SCT (Figure 4). The
patient is in sustaining complete remission according to
hematologic, radiologic and molecular criteria.
Conclusions
Extranodal manifestation of low grade non-Hodgkin
lymhomas in the central nervous system is extremely
rare. The synopsis of all diagnostic findings in the pre-
sented case resulted in the diagnosis of a splenic mar-
ginal zone lymphoma with meningeal lymphomatosis,infiltration of the temporal lobe and infiltration of the
cauda equina despite the unavailability of a spleen hist-
ology as the diagnostic hallmark of this disease. The
morphological features of the peripheral blood cells have
been already very suggestive of SMZL and the differen-
tial diagnosis of variant form of hairy cell leukemia was
excluded by immunophenotyping. Partial expression of
CD5 as observed in this patient is found in approxi-
mately 20% of SMZL cells, mantle cell lymphoma is not
plausible because of morphology and negativity for t
(11;14) in FISH analysis. The translocation t(2;7)(p11;
q21-22) is previously characterized in a few cases of
SMZL and in CD5-negative MBL [9,10]. This transloca-
tion seems to link CDK6 to the IG kappa locus [11]. Tri-
somy 3 is a current but not specific chromosomal
aberration which is found in a variety of B-cell lymph-
omas [9]. Summarized, the results of all analyses con-
firmed the extraordinary diagnosis of SMZL with
involvement of the central nervous system.
Only three cases with CNS manifestation of a SMZL
have been described in the literature so far. All of them
Figure 4 Detection of lymphoma cells in bone marrow, blood and CSF by specific rtPCR. BM: bone marrow, PB: peripheral blood, CSF:
cerebro-spinal fluid.
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a cerebral manifestation and another patient an infiltra-
tion of the optic nerve. The treatment results have been
different, two patients had good responses to chemo-
therapy and a third one had a refractory disease [12–14].
Normally, splenic marginal zone lymphomas have a fa-
vorable prognosis. Conventional therapy (splenectomy,
purine analogs or rituximab, antiviral therapy in con-
comitant HCV infection) is not curative, but can lead to
long lasting remissions. Adverse prognostic factors have
been identified. Chacón et al. found extranodal site in-
volvement (apart from liver and spleen) after splenec-
tomy reducing median overall survival to 52 months,
while overall survival in patients without extranodal site
involvement was not reached at 113 months [15]. Eleva-
tion of LDH at initial diagnosis is discussed as adverse
prognostic factor in a published scoring system [16]. Ag-
gressive treatment forms like high-dose therapy (HDT)
followed by autologous stem cell transplantation (auto-
SCT) is a valuable option for younger patients with
high-grade NHL of central nervous system [17]. This
therapeutical approach has no plausible curative poten-
tial in case of indolent lymphomas, however.
Due to the special features indicating the aggressive-
ness of the disease and the young age of our patient, we
recommended an intensive proceeding including therapy
with drugs penetrating excellently into the CSF (MTX,
Busulfan, Thiotepa, Fludarabine) followed by allogeneic
stem cell transplantation from an unrelated donor in
order to cure from lymphoma. SMZL disappeared com-
pletely, even on the molecular level (Figure 4, Figure 1).Graft-versus-leukemia/lymphoma-effects are essential
for the eradication of residual hematological malignan-
cies after allogeneic BSCT [18], but the information
about GvL-acitivity within the CNS is still limited. A
case of a PCNSL treated with allogeneic peripheral
BSCT has been described: the manifestation of acute
GvHD could be correlated with the disappearance of
intracerebral lymphoma [19]. Another group described
donor-derived lymphocytes in the cerebrospinal fluid
after transplantation [20]. Furthermore, the successful
treatment by allogeneic BSCT of patients with isolated
CNS relapse of acute leukemia has been published [21].
In a prior publication we reported the successful therapy
of CNS-relapse of high-grade NHL with alloSCT, immu-
nomodulation and irradiation [22]. The clinical and mo-
lecular remission of SMZL in this case strongly suggest
contribution of GvL-effects, however, the relative short
follow-up of three years allows no definite conclusion.
The actual case in conjunction with preceding publica-
tions should encourage the physicians involved into
therapy of lymphomas of the CNS to consider allogeneic
stem cell transplantation as a valuable salvage therapy
and as a possible primary therapy in high-risk patients.
Investigation of this approach in clinical trials and fur-
ther research about the activity of donor cells in the
CNS after alloSCT are mandatory.
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